Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Inventory (2023 - 2025)

Gyre Therapeutics (GYRE) has disclosed Change in Inventory for 3 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory rose 923.73% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 69.75% year-over-year, with the annual reading at $3.6 million for FY2025, 69.75% up from the prior year.
  • Change in Inventory for Q4 2025 was $1.2 million at Gyre Therapeutics, up from -$72000.0 in the prior quarter.
  • The five-year high for Change in Inventory was $1.5 million in Q1 2025, with the low at -$921000.0 in Q3 2023.
  • Average Change in Inventory over 3 years is $335250.0, with a median of $377000.0 recorded in 2024.
  • Peak annual rise in Change in Inventory hit 923.73% in 2025, while the deepest fall reached 111.32% in 2025.
  • Over 3 years, Change in Inventory stood at -$184000.0 in 2023, then soared by 164.13% to $118000.0 in 2024, then surged by 923.73% to $1.2 million in 2025.
  • According to Business Quant data, Change in Inventory over the past three periods came in at $1.2 million, -$72000.0, and $954000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.